Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1122)	8/7/1998 11:08:00 AM
From: Zvi Steinberg	Read Replies (2) \| Respond to of 1491

Here's from CBS Stock Watch: " "The company I'm about to mention, an Israeli biotechnology stock no less, has been a holding of mine for about six months. And I'm continuing to add to my position. It's Pharmos Corp. (PARS): interesting company with two products already approved by the U.S. Food & Drug Administration, revenues from these products this past quarter, and a drug in Phase II human trials that is based on, a-hem, cannabis. First, there are the two strong ophthalmic products approved by the FDA: Lotemax and Alrex. And this cannibis derivative, HU-211 (Hebrew University 211) is into Phase II with strong outcomes behind it. And the stock, perhaps due to lack of Wall Street awareness (and) justifiable suspicion of anything biotechnological is languishing." So says C. Maher, who last checked in with us when he discussed prospects for Internet company Infoseek." cbs.marketwatch.com